BOSTON and LACEY, Wash., April 6 /PRNewswire/ -- AdipoGenix Inc. and Unigen Pharmaceuticals, Inc. today announced that they have entered into an agreement for the joint discovery and development of natural products that target human fat. AdipoGenix is a biopharmaceutical company developing small molecule therapies for obesity, type 2 diabetes and associated morbidities, and Unigen is a leading natural products research and development facility and supplier of proprietary, biologically active plant-derived ingredients to the natural products and pharmaceutical industries.
Under the terms of the agreement, AdipoGenix and Unigen will equally share in the costs and profits for the discovery, development, and commercialization of products resulting from the collaboration. AdipoGenix will apply its proprietary human fat cell-based technologies to discover natural substances that reduce the fat content of human fat cells from Unigen’s collection of medicinal plant extracts. Unigen will identify and produce active molecules from active extracts that are discovered and AdipoGenix will characterize mechanisms of action and molecular targets for active molecules taken into development. AdipoGenix will retain world wide rights for the development and commercialization of any pharmaceutical products, and Unigen will retain world wide rights for the commercialization of any cosmeceutical or nutraceutical products that result from the collaboration. Additional terms were not disclosed.
“AdipoGenix has a very promising approach to discovering new therapeutics for obesity with their human fat cell-based technology. We believe that this collaboration is a tremendous opportunity to develop novel plant-derived products that address this important health concern,” said Regan Miles, Unigen’s President and Chief Operating Officer. “This is an important part of our strategy to expand our offerings in the large and growing market for natural weight control products.”
“Unigen has an extensive collection of extracts from medicinal plants from around the world. Through this collaboration, we gain access to a unique source of natural substances, and expand our opportunities to discover and develop novel pharmaceuticals that reduce the fat content of human fat cells,” said Ed Cannon, Ph.D., CEO of AdipoGenix. “Furthermore, we are pleased to have in Unigen, a partner that allows us to leverage our proprietary human fat cell-based technologies into the $25-plus billion market for nutraceuticals and cosmeceuticals.”
About Unigen Pharmaceuticals, Inc.
Unigen Pharmaceuticals, Inc. (http://www.UnigenPharma.com) is a leading natural products research and development company and proprietary ingredients supplier. The company is dedicated to the discovery of botanically derived therapeutic compounds that address consumer health needs and help improve the quality of human life. Its research and discovery process includes extensive work at both the human cell and gene level. Unigen and sister company Aloecorp, Inc. each focus on identifying and studying the unique ingredients of medicinal botanicals (Aloecorp’s focus is on Aloe vera) and then formulating proprietary, patented raw materials for use in cosmeceutical, nutraceutical and pharmaceutical products.
About AdipoGenix Inc.
AdipoGenix is a Boston-based biopharmaceutical company developing pharmaceuticals that target human fat tissue to treat obesity and its co-morbidities, including diabetes and cardiovascular disease. Through its proprietary human fat cell-based technology, AdipoGenix identifies nontoxic, small molecule compounds that reduce the fat content in human fat tissue, which is expected to provide therapeutic benefit for these important diseases.
On the Net: http://www.AdipoGenix.comhttp://unigenpharma.com Contacts: For AdipoGenix: Ed Cannon Kari Watson President and CEO MacDougall Biomedical Communications AdipoGenix Inc. (508) 647-0209 617-638-6394 kwatson@macbiocom.com For Unigen: Regan Miles Qi Jia President and COO Chief Scientific Officer Unigen Pharmaceuticals Inc. Unigen Pharmaceuticals Inc. 360-486-8200 360-486-8200 reganmiles@earthlink.netqij@upi1.com
AdipoGenix Inc.
CONTACT: Ed Cannon, President and CEO of AdipoGenix Inc., +1-617-638-6394;or Kari Watson of MacDougall Biomedical Communications, +1-508-647-0209,kwatson@macbiocom.com; or Regan Miles, President and COO,reganmiles@earthlink.net, or Qi Jia, Chief Scientific Officer, qij@upi1.comboth of Unigen Pharmaceuticals Inc., +1-360-486-8200
